Skip to medicine information
Protein Simülasyonları ve 3D Modelleme Medicine information · English

Tofacitinib

Uses and differences between formulations

Tofacitinib is a Janus kinase inhibitor available as Xeljanz tablets or oral solution and Xeljanz XR extended-release tablets. The U.S. indications include selected inflammatory arthritis disorders and ulcerative colitis. Eligibility depends on diagnosis, age, previous treatment and the prescribed presentation. The extended-release product is not a substitute to make independently for the immediate-release tablet or oral solution.

Important interaction mechanisms

Tofacitinib exposure rises with strong CYP3A4 inhibitors. Exposure also rises when a medicine inhibits CYP3A4 moderately and CYP2C19 strongly; fluconazole is a specifically studied example. These combinations may require a prescriber-directed adjustment and monitoring. Strong CYP3A4 inducers, such as rifampin, can reduce exposure and clinical response, and are not recommended. A pharmacist should review prescription medicines, over-the-counter products and supplements together rather than considering each list separately.

Immunosuppression and monitoring

The label does not recommend combining tofacitinib with biologic disease-modifying drugs or potent immunosuppressants such as azathioprine, tacrolimus or ciclosporin. This is different from assuming that every accompanying arthritis medicine is forbidden. Some studied regimens include conventional medicines such as methotrexate, and the clinical team decides the appropriate combination. Baseline and follow-up evaluation can include tuberculosis screening, blood counts, liver tests and lipid measurements.

Serious symptoms that need assessment

The U.S. prescribing information contains major warnings about serious infection, malignancy, cardiovascular events, thrombosis and mortality. Some comparative safety findings came from a cardiovascular-risk-enriched rheumatoid arthritis population; they should not be turned into a numerical prediction for an individual visitor. Seek prompt medical help for persistent fever or serious infection symptoms, chest pain, sudden breathlessness, leg swelling, stroke-like symptoms or a severe allergic reaction. New abdominal symptoms also need assessment, particularly with diverticulitis history or NSAID use.

Pregnancy, breastfeeding and everyday questions

Human pregnancy evidence remains limited, while animal studies identified reproductive risks. Pregnancy planning should consider both the medicine and the underlying inflammatory disease. Published evidence shows tofacitinib in human milk, and the current U.S. label advises against breastfeeding during treatment and for a formulation-specific interval afterwards. Common adverse reactions include respiratory infections, headache and diarrhoea; monitoring can also detect blood-count or cholesterol changes. No simple website alcohol score can replace an assessment of liver health and the full treatment regimen.

Sources and scope

This English summary describes the referenced U.S. product information; local authorisations, age limits and formulations may differ. It is not a dosing guide or an independent clinical review. A missing interaction entry does not establish safety.